aetna™

AVASTIN™ (bevacizumab)
MVASI™ (bevacizumab-awwb)
ZIRABEV™ (bevacizumab-bvzr)
Medication Precertification Request

(All fields must be completed and legible for Precertification Review)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy, Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:	DOB:	
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	Email:
Patient Current Weight: _____ lbs or _____ kgs Patient Height: _____ inches or _____ cms		Allergies:	

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured:

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured:

Medicare: ☐ Yes ☐ No If yes, provide ID #:

Medicaid: ☐ Yes ☐ No If yes, provide ID #:

C. PRESCRIBER INFORMATION

First Name:		Last Name: *(Check One)*: ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.			
Address:		City:		State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	

Specialty *(Check one)*: ☐ **Oncologist** ☐ **Ophthalmologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:

☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*

☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for: ☐ **AVASTIN (bevacizumab)** ☐ **MVASI (bevacizumab-awwb)** ☐ **ZIRABEV (bevacizumab-bvzr)**
Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other where applicable.

Primary ICD Code: _____ **Secondary ICD Code:** _____ **Other ICD Code:** _____

G. CLINICAL INFORMATION - Required clinical information must be completed in its entirety for all precertification requests.

For Initiation Requests (clinical documentation required for all requests):

Ophthalmic disorders:

☐ Choroidal neovascularization (CNV) (including myopic choroidal neovascularization (mCNV), angioid streaks, choroiditis [including choroiditis secondary to ocular histoplasmosis], idiopathic degenerative myopia, retinal dystrophies, rubeosis iridis, pseudoxanthoma elasticum, and trauma)
☐ Diabetic macular edema
☐ Macular edema following retinal vein occlusion (RVO)
☐ Neovascular (wet) age-related macular degeneration (AMD)
☐ Neovascular glaucoma
☐ Polypoidal choroidal vasculopathy
☐ Proliferative diabetic retinopathy
☐ Retinopathy of prematurity

Oncology indications:

☐ AIDS-related Kaposi sarcoma
☐ Anaplastic glioma
☐ Angiosarcoma
↳ ☐ Yes ☐ No Will the requested medication be given as a single agent therapy?
☐ Breast cancer

Continued on next page

aetna™

AVASTIN™ (bevacizumab)
MVASI™ (bevacizumab-awwb)
ZIRABEV™ (bevacizumab-bvzr)
Medication Precertification Request

(All fields must be completed and legible for Precertification Review)

Aetna Precertification Notification
Phone: 1-866-752-7021
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Phone: 1-866-503-0857
FAX: 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ Cervical cancer
→ ☐ Yes ☐ No Does the patient have persistent, recurrent, or metastatic disease?
→ Please select: ☐ persistent disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above

☐ Colorectal cancer (including small bowel adenocarcinoma, appendiceal carcinoma, and anal adenocarcinoma)

☐ Glioblastoma

☐ Endometrial cancer
→ ☐ Yes ☐ No Does the patient have progressive, advanced, or recurrent disease?
→ Please select: ☐ progressive disease ☐ advanced disease ☐ recurrent disease ☐ none of the above

☐ Epithelial ovarian cancer (including carcinosarcoma [malignant mixed Müllerian tumors], clear cell carcinoma, mucinous carcinoma, grade 1 endometrioid carcinoma, low-grade serous carcinoma, borderline epithelial tumors [low malignant potential] with invasive implants, and malignant sex cord-stromal tumors)

☐ Fallopian tube cancer

☐ Hepatocellular carcinoma
→ ☐ Yes ☐ No Will the requested medication be given in combination with atezolizumab?

☐ Intracranial and spinal ependymoma (excludes subependymoma)

☐ Leptomeningeal metastases

☐ Limited and extensive brain metastases

☐ Low-grade (WHO Grade II) infiltrative supratentorial astrocytoma/oligodendroglioma

☐ Malignant pleural mesothelioma
→ ☐ Yes ☐ No Will the requested medication be given in combination with pemetrexed and either cisplatin or carboplatin, followed by single agent maintenance therapy?

☐ Medulloblastoma

☐ Meningiomas

☐ Metastatic spine tumors

☐ Non-squamous non-small cell lung cancer (NSCLC)
→ ☐ Yes ☐ No Does the patient have recurrent, advanced, or metastatic disease?
→ Please select: ☐ recurrent disease ☐ advanced disease ☐ metastatic disease ☐ none of the above

☐ Pericardial mesothelioma

☐ Peritoneal mesothelioma

☐ Primary central nervous system lymphoma

☐ Primary peritoneal cancer

☐ Renal cell carcinoma (kidney cancer)
→ ☐ Yes ☐ No Does the patient have relapsed or metastatic disease? ☐ relapsed disease ☐ metastatic disease ☐ none of the above

☐ Solitary fibrous tumor or hemangiopericytoma
→ ☐ Yes ☐ No Will the requested medication be given in combination with temozolomide?

☐ Tunica vaginalis testis mesothelioma

☐ Vaginal cancer
→ ☐ Yes ☐ No Does the patient have persistent, recurrent, or metastatic disease?
→ Please select: ☐ persistent disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above

☐ Uterine cancer
→ ☐ Yes ☐ No Does the patient have progressive, advanced, or recurrent disease?
→ Please select: ☐ progressive disease ☐ advanced disease ☐ recurrent disease ☐ none of the above

☐ Vulvar cancer
→ ☐ Yes ☐ No Does the patient have unresectable locally advanced, recurrent, or metastatic disease?
→ Please select: ☐ unresectable locally advanced disease ☐ recurrent disease ☐ metastatic disease ☐ none of the above

☐ Other

For Continuation Requests:

Ophthalmic disorders:

☐ Yes ☐ No Has the patient demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss)?

Oncology indications:

☐ Yes ☐ No Has the patient experienced a clinical benefit or not experienced an unacceptable toxicity with the requested medication?
→ Please select: ☐ has experienced a clinical benefit ☐ has not experienced an unacceptable toxicity ☐ none of the above

H. ACKNOWLEDGEMENT

Request Completed By *(Signature Required)*: _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.